Can we cure the price problem for new cancer technologies?

Access status:

Open Access

Field	Value	Language
dc.contributor.author	Sullivan, Richard
dc.date.accessioned	2017-10-26
dc.date.available	2017-10-26
dc.date.issued	2017-10-26
dc.identifier.uri	http://hdl.handle.net/2123/17325
dc.description	Seminar presentation + oral recording	en
dc.description.abstract	In this lecture we will explore the evidence for the divergences and deficits, investor policy towards pricing and what determines price (such as power relationships), the conflicted relationship between the research communities, patient organisations, the media, regulatory authorities and pharmaceutical sector, and the data around declining value and affordability. What solutions can and should be imposed at both national and supra-national levels?	en
dc.description.sponsorship	Cancer Council Australia	en
dc.language.iso	en_AU	en
dc.rights	Other
dc.subject	cancer	en
dc.subject	systems of care	en
dc.subject	outcomes	en
dc.subject	healthcare	en
dc.subject	medicine	en
dc.subject	new technology	en
dc.title	Can we cure the price problem for new cancer technologies?	en
dc.type	Presentation	en
usyd.faculty	Faculty of Medicine and Health, Centre for Disability Research and Policy	en
usyd.department	Menzies Centre for Health Policy	en